Literature DB >> 35170052

Association between ultrasound quality and test performance for HCC surveillance in patients with cirrhosis: a retrospective cohort study.

Nicolas Chong1,2, Haley Schoenberger1,2, Sruthi Yekkaluri1, David T Fetzer3, Nicole E Rich1,2, Takeshi Yokoo3, Purva Gopal4, Carrie Manwaring1, Lisa Quirk1, Amit G Singal1,2.   

Abstract

BACKGROUND: Ultrasound visualisation is limited in approximately 20% of patients with cirrhosis undergoing hepatocellular carcinoma (HCC) surveillance; however, it is unknown if impaired visualisation directly impacts test performance. We aimed to evaluate the association between ultrasound visualisation and surveillance test performance.
METHODS: We performed a retrospective cohort study among patients with cirrhosis, with or without HCC, who underwent ultrasound-based surveillance at two large health systems between July 2016 and July 2019. Ultrasound visualisation assessment was recorded by interpreting radiologists using the ultrasound LI-RADS Visualisation score. We performed logistic regression analyses to evaluate the association between ultrasound visualisation and diagnostic test performance. We assessed sensitivity for HCC detection among ultrasounds performed in the year prior to HCC diagnoses and specificity using ultrasounds in those without HCC.
RESULTS: Among 186 patients with HCC, severely limited visualisation (Vis Score C) on ultrasound prior to HCC diagnosis was associated with increased odds of false-negative results, that is lower sensitivity (OR 7.94, 95% CI 1.23-51.16) in multivariable analysis. Ultrasound sensitivity with visualisation scores A or B exceeded 75%, compared to only 27.3% with visualisation score C. Among 2052 cirrhosis patients without HCC, moderate visualisation limitations (Vis score B) were associated with increased odds of false-positive results (OR 1.60, 1.13-2.27), although specificity exceeded 95% across all visualisation scores.
CONCLUSIONS: Impaired ultrasound visualisation is associated with worse surveillance test performance. Alternative blood-based biomarkers and imaging strategies are needed for patients at risk for ultrasound-based surveillance failure.
© 2022 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2022        PMID: 35170052     DOI: 10.1111/apt.16779

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  5 in total

Review 1.  Emerging liquid biopsy techniques for early detection of hepatocellular carcinoma, prognostication, and disease monitoring.

Authors:  Ashwini Arvind; Amit G Singal
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-07-22

2.  The growing threat of non-alcoholic fatty liver disease-related hepatocellular carcinoma.

Authors:  Margaret L P Teng; Kai En Chan; Darren J H Tan; Daniel Q Huang
Journal:  Hepatobiliary Surg Nutr       Date:  2022-10       Impact factor: 8.265

3.  Reply.

Authors:  Amit G Singal; Neehar D Parikh
Journal:  Hepatology       Date:  2022-04-24       Impact factor: 17.298

4.  Clinical Characteristics and Outcomes of Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in the United States.

Authors:  Mohammad A Karim; Amit G Singal; Hye Chung Kum; Yi-Te Lee; Sulki Park; Nicole E Rich; Mazen Noureddin; Ju Dong Yang
Journal:  Clin Gastroenterol Hepatol       Date:  2022-03-17       Impact factor: 13.576

5.  Comparison of a multitarget blood test to ultrasound and alpha-fetoprotein for hepatocellular carcinoma surveillance: Results of a network meta-analysis.

Authors:  Amit G Singal; Benjamin Haaland; Neehar D Parikh; A Burak Ozbay; Carol Kirshner; Shubham Chakankar; Kyle Porter; Jagpreet Chhatwal; Turgay Ayer
Journal:  Hepatol Commun       Date:  2022-08-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.